The Seneca Managed Storage EIS Fund

An alternative investment fund specialising in EIS qualifying investment into managed storage facilities


The Seneca Managed Storage EIS Fund provides investors with the ability to invest in a number of managed storage facilities whilst benefiting from both the tax reliefs available under EIS and the underlying asset value represented by the freehold or long leasehold storage sites.

The Seneca EIS Portfolio Service is a compelling investment option which combines the significant tax benefits available under the Enterprise Investment Scheme with the potential for attractive returns. We do not factor tax reliefs into our targeted investment returns and consider each opportunity on its merit regardless of the tax reliefs available. We offer a discretionary investment management service where the shares are held by a nominee of our independent custodian to the investors order.


Read further

Our EIS Brochure and Application form are now available to download

The Seneca EIS Portfolio Service

The Seneca Managed Storage EIS Fund

Live Portfolio

A Selection from our EIS Investment Portfolio

Investment Approach Image

Investment Approach

Targeting more established and stable businesses with good growth potential is central to our investment strategy

Read More

Charges Image


Our EIS portfolio charging structure is low and designed to align Seneca to our Investors Objectives

 Read More

Key Features Image

Key Features

Enterprise Investment Schemes grant generous tax benefits in return for providing equity funding to qualifying businesses

 Read More

Risk Factors Image

Risk Factors

You should not invest in this product unless you have thought carefully about whether you can afford it, and whether it is right for you

Read more

Unrivalled Experience

Our team brings together decades of success in providing investment solutions and success for investors

Latest News

October 20th 2016

Development candidate chosen for leukaemia program

Redx, the drug development company, is pleased to announce that it has identified a drug development candidate for its reversible Bruton's tyrosine kinase ("BTK") inhibitor program. The compound, named RXC005, has the potential to treat the majority of patients suffering...

Read More

Acceleris Tweets

Congratulations to our colleagues at @senecapartners for their double award win last week…

Acceleris secures successful fundraise for specialist technology services company

Seneca Tweets

SENECA AT THE DOUBLE - Seneca Partners won two awards at the Insider North West Dealmaker Awards.……

So pleased to have become double award winners tonight. Deal of the Year (sub £10m) for our investment in to Foodpa……

Very proud to have won "Alternative Finance Provider of the Year" at the dealmakers

Get in Touch

For administrative and shareholder queries, please contact the Seneca EIS Team

For sales or other general queries, please contact the Seneca EIS Team or LGBR Capital

Newsletter Sign Up

Stay Social